Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 86 member B3, pseudogene (FAM86B3P) is classified as a pseudogene, meaning it resembles a protein-coding gene in sequence but is not believed to encode a functional protein.[1][5] Pseudogenes arise from duplication or retrotransposition events and generally acquire disabling mutations that render them nonfunctional.[7] FAM86B3P does not have known, validated biological activity or involvement in recognized signaling pathways, nor is it regarded as a therapeutic target in current biomedical practice. It is not considered a disease gene or a biomarker, and there is no evidence of drug interaction or clinical relevance. As a result, this entry is not appropriate as a drug target, and its listing as a target or receptor is likely incorrect.[1][5][7] Key points: - FAM86B3P is a pseudogene without functional protein-coding ability or known biological function. - It is not a therapeutic target, receptor, enzyme, transporter, or involved in clinical disease. - There are no drugs, mechanisms, biomarkers, or safety concerns associated with this pseudogene.[1][5][7]
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 86 member B3, pseudogene (FAM86B3P).